Reversal Agents
About
-
Direct oral anticoagulants (DOACs) are increasingly used for prevention and treatment of venous thromboembolism and for prevention of stroke in patients with non-valvular atrial fibrillation.
Load moreDirect oral anticoagulants (DOACs) are increasingly used for prevention and treatment of venous thromboembolism and for prevention of stroke in patients with non-valvular atrial fibrillation.
Anticoagulant reversal should only be considered with life-threatening bleeds, with bleeds that fail to respond to usual measures, and in patients requiring urgent surgery.
Idarucizumab is licensed for dabigatran reversal. The Factor Xa inhibitor andexanet alfa has recently been licensed in the US for reversal of rivaroxaban, apixaban and edoxaban.
Load Less
Videos
Reversal Agents - Selected Papers
-
Burnett A, Siegal D, Crowther M. BMJ 2017;357:j2216.
-
Niessner A, Tamargo J, Morais J, et al. Eur Heart J 2017;38:1710–6.
-
Pollack CV Jr, Reilly PA, van Ryn J, et al. N Engl J Med 2017;377:431-41.
-
Glund S, Stangier J, Schmohl M, et al. Blood 2014;124:344.
Reversal Agents - Idarucizumab for Dabigatran Reversal
-
Glund S, Stangier J, Schmohl M, et al. Blood 2014;124:344.
-
Eikelboom J, Quinlan JD, van Ryn J, Weitz JI. Circulation 2015;132:2412–22.
-
Pollack CV Jr, Reilly PA, Bernstein RA, et al. Thromb Haemost 2015;114:198–205.
-
Glund S, Moschetti V, Norris S, et al. Thromb Haemost 2015;113:943–51.
Reversal Agents - Andexanet Alfa for Factor Xa Inhibitors
-
Crowther M, Levy GG, Lu G, et al. Blood 2014;124:4269.
-
Connolly SJ, Milling TJ, Eikelboom J, et al. N Engl J Med 2016;375:1131–41.
Reversal Agents - Ciraparantag for Factor Xa Inhibitors
-
Ansell JE, Laulicht BE, Bakhru SH, et al. Thromb Res 2016;146:113–8.
-
Ansell JE, Bakhru SH, Laulicht BE, et al. Thromb Haemost 2017;117:238–45.
Reversal Agents - Guidelines/expert recommendations
-
Weitz JI. Semin Respir Crit Care Med 2017;38:40–50.
-
Ageno W, Buller HR, Falanga A, et al. Thromb Haemost 2016;116:1003–10.
-
Levy JH, Ageno W, Chan NC, et al. J Thromb Haemost 2016;14:623–7.
-
Raval AN, Cigarroa JE, Chung MK, et al. Circulation 2017;135:e604–33.
